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Abstract: Recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC) 
continues to be a source of significant morbidity and mortality worldwide. Agents that target 
the epidermal growth factor receptor (EGFR) have demonstrated beneficial effects in this set-
ting. Cetuximab, a monoclonal antibody against the EGFR, improves locoregional control and 
overall survival when used as a radiation sensitizer in patients with locoregionally advanced 
HNSCC undergoing definitive radiation therapy with curative intent. Cetuximab is also active 
as monotherapy in patients whose cancer has progressed on platinum-containing therapy. In 
the first-line setting for incurable HNSCC, cetuximab added to platinum-based chemotherapy 
significantly improves overall survival compared with standard chemotherapy alone. These 
positive results have had a significant impact on the standard of care for advanced HNSCC. In 
this review, we will discuss the mechanism of action, clinical data and common toxicities that 
pertain to the use of cetuximab in the treatment of advanced incurable HNSCC.
Keywords: cetuximab, squamous cell carcinoma of the head and neck, epidermal growth 
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Introduction
Squamous cell carcinoma of the head and neck (HNSCC) is diagnosed in over 
500,000 patients worldwide each year, accounting for 5% of all malignancies.1 In 
the United States, the estimated incidence was 45,660 new cases and 11,210 deaths 
in 2007. The most common primary site is the oral cavity. Risk factors for HNSCC 
include tobacco and alcohol use,2 with increasing evidence for a pathogenic role of 
the human papillomavirus (HPV) in patients lacking the usual risk factors.3
SEER (surveillance, epidemiology and end results) data have shown an increase in 
the annual incidence of base of tongue and tonsil cancers by 2.1% and 3.9% respectively, 
from 1973 to 2001 among white individuals aged 20 to 44 years, whereas the incidence 
at other sites has declined. The change has been attributed to the increasing prevalence 
of human papillomavirus (HPV) infection in developed countries, the practice of oral 
sex and an increasing number of sexual partners.4 Approximately 25% of all HNSCC 
are associated with HPV and up to 60% of oropharynx cancers (particularly those of 
lingual and palatine tonsils) have been associated with HPV . HPV-related HNSCC tend 
to be poorly differentiated, have basaloid features and present at a lower T stage.5,6 
Patients with HPV-related head and neck cancers generally have better treatment 
response and overall survival.6
The main site of treatment failure in HNSCC is locoregional recurrence. With 
improvements in locoregional treatment and control, failure at distant sites with Biologics: Targets & Therapy 2010:4 174
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metastatic disease is becoming more prevalent. A minority 
of patients with locoregional failure can be salvaged with 
surgery or re-irradiation. Until very recently, systemic 
therapy options were very limited for patients with recur-
rent disease who were not candidates for locoregional 
approaches. A series of landmark studies have established 
the role of cetuximab, a monoclonal antibody targeting the 
epidermal growth factor receptor (EGFR), in the treatment of 
locoregionally advanced and potentially curable HNSCC as 
well as in patients with incurable recurrent and/or metastatic 
HNSCC.7 This review summarizes current data available 
regarding the evolving use of cetuximab in the treatment of 
incurable HNSCC. Other reviews have nicely summarized 
the role of cetuximab in combination with radiation in the 
curative treatment of HNSCC.8–10
EGFR and HNSCC
The EGFR is a transmembrane cell surface receptor belong-
ing to the erbB family of type 1 receptor tyrosine kinases, 
which also includes c-erbB2 (Her2/neu), c-erbB3 and 
c-erbB4. Ligands for the EGFR include EGF itself, trans-
forming growth factor-α (TGF-α), amphiregulin, epiregulin, 
betacellulin and heparin-binding EGF-like growth factor 
(HB-EGF).11 EGF and TGF-α, often co-expressed with 
EGFR, are produced by normal and tumor tissue epithelial 
cells. Higher levels of these ligands are found in tumor 
and surrounding stroma compared with normal mucosa. 
EGFR2 (erbB2 or Her2/neu) has no known natural ligands. 
Neuregulins (NRG) and heregulin are the ligands for ErbB3 
and ErbB4.
Four distinct protein domains comprise the EGFR extra-
cellular ligand-binding region. Domains I and III are leucine-
rich and provide the binding sites for growth factor ligands. 
Cooperation between domains I and III is required for high 
affinity binding of EGF.12 Most of the anti-EGFR antibodies 
in the clinic target domain III and thereby interfere with EGF 
and other ligand binding. Ligand binding is followed by either 
homodimerization or heterodimerization with another mem-
ber of the EGFR tyrosine kinase receptor family.13,14 EGFR 
stimulation results in multiple cellular responses including 
angiogenesis, proliferation, migration, and resistance to 
apoptosis. Processes that are activated by EGFR stimulation 
include signal transduction pathways for PI3K-Akt (related 
to survival and apoptosis evasion) and Ras-Raf-MEK-MAPK 
(relating to proliferation).15 In addition, there is an interac-
tion between EGFR expression and signal transducers and 
activators of transcription 3 (eg, STAT3), which play a role 
in the regulation of transcription of genes involved in cell 
cycle progression such as Fos, Cyclin-D, CDC25A, c-Myc 
and Pim1 and the upregulation of antiapoptotic genes such 
as BCL2.16,17
EGFR can also translocate to the nucleus where it acti-
vates or represses the production of various effector proteins. 
One key nuclear function of EGFR is phosphorylation and 
activation of DNA-dependent protein kinase (DNA-PK), 
an enzyme that is involved in repair of breaks in double-
stranded DNA caused by radiation and chemotherapy.18,19 
EGFR localizing to the nuclear compartment can also enter 
transcriptional complexes and bind to the promoter region 
of cyclin D1 to promote cell cycle progression and increase 
cellular proliferation.20 EGFR inhibition delays the repair 
of chemotherapy-induced DNA damage via modulation of 
DNA repair genes such as XRCC1 and ERCC1, which could 
explain some of the increased activity of cisplatin when com-
bined with EGFR inhibitors such as cetuximab.21–23
Elevated EGFR expression detected by immunohisto-
chemistry is present in over 90% of HNSCC specimens 
and the level of expression is associated with inferior 
survival, radioresistance and locoregional failure.24–27 
Unlike lung adenocarcinomas in which activating muta-
tions of the EGFR create ligand independent pathway 
activity,28,29 such EGFR mutations in HNSCC specimens 
are distinctly uncommon and therefore do not explain the 
role of the EGFR in the pathogenesis of HNSCC.30,31 Thus, 
the excess activity of the EGFR and related pathways in 
HNSCC appears to be mostly ligand-dependent, or due 
to receptor over-expression. A variant of EGFR has been 
described – EGFRvIII – which is weakly constitutively 
active in a ligand-independent manner. This truncated form 
of EGFR was present in 42% of HNSCC cells in one series. 
Cells that harbor this mutant are likely to be less responsive 
to treatment with cetuximab, since EGFRvIII has a deletion 
of exons 2 through 7, encompassing the ligand-binding 
domain and the cetuximab-binding site. Further study of 
the role of EGFRvIII in the pathogenesis and response to 
treatment in HNSCC is clearly indicated.32
Multiple preclinical studies have shown that EGFR 
inhibition sensitizes HNSCC to the effects of ionizing 
radiation.7,33–35 Similarly, EGFR inhibition with cetuximab 
demonstrated synergy in combination with chemotherapy in 
killing HNSCC cells in xenograft tumor models. In mouse 
A431 xenografts of HNSCC, the combination of cetuximab 
and cisplatin led to growth inhibition in excess of that 
achieved with either agent alone.36 Similar enhancement by 
cetuximab of the activity of cisplatin and 5-FU was observed 
in another cell line, human tongue SCC-25.37Biologics: Targets & Therapy 2010:4 175
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Cetuximab
Cetuximab is a chimeric monoclonal antibody (65% human 
and 35% murine) constructed on an immunoglobulin (Ig) 
G1 framework, which targets an extracellular epitope in the 
EGFR ligand-binding domain.38 Cetuximab blockade of the 
EGFR results in inhibition of tumor growth, metastasis, DNA 
damage repair and angiogenesis.39,40
Several mechanisms that contribute to the anti-tumor 
activity of cetuximab have been identified. A major mecha-
nism is interference by cetuximab with the binding of natural 
ligands to the receptor itself, thereby disrupting EGFR sig-
naling pathways.41 Another mechanism involves depletion 
of the targeted receptors from the cell surface via induction 
of receptor endocytosis.42 Finally, cetuximab’s construction 
on an IgG1 framework potentially allows this agent to medi-
ate antibody-dependent cell-mediated cytotoxicity (ADCC) 
via recruitment of natural killer cells and macrophages.43,44 
ADCC is influenced by Fcγ receptor polymorphisms that 
are known to be clinically relevant in follicular lymphoma 
and metastatic breast cancer and modulate the treatment 
response to antibodies such as rituximab and trastuzumab. 
A polymorphism in Fc gammaR IIIa receptor, Fc gammaR 
IIIa-158, which is expressed on NK cells and associated 
with enhanced ADCC, is linked with increased cetuximab 
activity in HNSCC cells in vitro.45 Clinically, variation in 
FcγR polymorphisms in patients with HNSCC treated with 
cetuximab could potentially account for some portion of the 
varying response rates that are observed in patients. Addi-
tional clinical data will be needed, however, before we can 
assign a definite role to ADCC in the treatment response to 
cetuximab in patients with HNSCC.
There are several other EGFR targeting antibodies 
in varying stages of clinical development. Cetuximab, 
matuzumab and nimotuzumab are constructed on an IgG1 
framework that potentially allows these agents to mediate 
ADCC via natural killer (NK) cells and macrophages. By 
contrast, panitumumab, a fully humanized anti-EGFR anti-
body constructed on an IgG2 framework, will not mediate 
ADCC.46 Panitumumab is currently FDA-approved for use 
in metastatic colorectal in colorectal cancer, and unlike 
cetuximab is not associated with infusion related hyper-
sensitivity reactions. IMC-11F8 is a newer fully human-
ized anti-EGFR IgG1 monoclonal antibody that has been 
tested in the phase 1 setting,47 and is now being studied in 
phase 2 and 3 studies in colorectal and non-small cell lung 
cancer, respectively. Another novel anti-EGFR antibody, 
mAb 806, is active against cell lines expressing the mutant 
variant EGFRvIII as well as cell lines in which wild type 
EGFR is over-expressed.48 Cetuximab, nimotuzumab, pani-
tumumab and matuzumab all prevent ligand binding via 
interactions with EGFR domain III, and mAb 806 interferes 
with receptor function via interactions with domain II.49–52 
The clinical significance of these molecular interactions 
of antibody and receptor is unknown and is the subject of 
ongoing basic research.
Cetuximab in the treatment  
of locally advanced disease
In 2006, Cetuximab was approved for use in combination 
with radiation therapy in patients with locally advanced 
HNSCC. This followed a pivotal phase III international 
trial, conducted by Bonner et al, in which 424 patients with 
locally advanced disease were randomized between defini-
tive radiation and concurrent radiation with cetuximab (given 
at 400 mg/m2 loading dose followed by 250 mg/m2 weekly 
for 8 planned doses).7 Cetuximab plus radiation improved 
the duration of loco-regional control from 14.9 to 
24.4 months (P = 0.005) and improved median survival from 
29.3 to 49 months (P = 0.03). There was no difference in the 
rates of distant metastatic disease in the two arms. Notably, 
the acute toxicities of radiation were not exacerbated by the 
addition of cetuximab. In a retrospective subset analysis, the 
hazard ratios favored the addition of cetuximab to the altered 
fractionation radiation regimens. This landmark study was 
the first to provide proof of principle data for the activity of 
cetuximab with radiation in the curative setting.
As cetuximab and cisplatin have different mechanisms 
of action and non-overlapping toxicity profiles, there has 
been interest in combining both agents with radiation. An 
exploratory phase II study from MSKCC enrolled 22 patients 
with locally advanced HNSCC (86% with stage IV disease) 
to receive cisplatin (100 mg/m2 every 3 weeks) and cetux-
imab (400 mg/m2 followed by 250 mg/m2 weekly) along with 
definitive radiation.53 Three-year overall survival and loco-
regional control rates were unusually positive at 76% and 
71% respectively. Adverse events resulted in the premature 
termination of this trial (including 2 on-study deaths, one 
from pneumonia and one of unknown cause).
A preliminary safety analysis of ECOG 3303, a phase II 
study of 61 patients with locally advanced HNSCC has 
also been reported.54 Enrolled patients received cisplatin 
(75 mg/m2 every 3 weeks) and cetuximab (400 mg/m2 
  followed by 250 mg/m2 weekly) along with definitive radia-
tion. In the absence of disease progression or unacceptable 
toxicity, patients continued weekly maintenance cetuximab 
for six months. Results indicate expected grade 3/4 toxicities Biologics: Targets & Therapy 2010:4 176
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of anemia, neutropenia, hypomagnesemia, hyponatremia, 
rash, fatigue and mucositis along with two late grade 4 toxici-
ties (pharynx pain and laryngeal edema), and one attributable 
grade 5 event (neutropenic fever). Early efficacy data seem 
promising with median progression-free survival (PFS) of 
15.3 months.
The RTOG 0522 (NCT00265941) study is a large, ran-
domized phase III trial that randomized patients to receive 
either concurrent accelerated radiation and cisplatin or con-
current accelerated radiation, cisplatin and cetuximab. The 
data are currently not mature and analysis is ongoing. It is 
hoped that this study will define the role and feasibility of 
cetuximab when combined with definitive cisplatin-based 
chemoradiation.
At this time, it is not known whether cetuximab and 
radiation is equivalent to cisplatin and radiation and there 
are unfortunately no prospective trials ongoing or planned to 
examine this important question. An interesting retrospective 
institutional analysis from MSKCC compared the outcome 
of 125 patients who received cisplatin (100 mg/m2 every 
3 weeks) with radiation to 50 patients who received cetux-
imab (400 mg/m2 loading dose and 250 mg/m2 weekly) with 
radiation.55 Recognizing that these were two different patient 
populations, multivariate analysis to address prognostic 
imbalances was performed. Despite this adjustment, results 
for local failure (LF), disease-free survival (DFS) and overall 
survival (OS) all favored the cisplatin arm (P  0.0001 for 
LF and DFS, P = 0.0017 for OS). Thus, definitive radiation 
with cisplatin chemotherapy currently remains the treatment 
of choice for medically fit patients.
Given its established activity when combined with 
radiation and chemotherapy, there is considerable interest 
in adding cetuximab to induction chemotherapy regimens. 
In 2008, Argiris et al reported preliminary safety results of a 
phase II trial in which 39 patients received induction cisplatin 
(75 mg/m2 every 3 weeks for 3 cycles), docetaxel (75 mg/m2 
every 3 weeks for 3 cycles) and cetuximab (400 mg/m2 load-
ing and 250 mg/m2 weekly).56 This was followed by radiation 
with concurrent cisplatin (30 mg/m2 weekly) and cetuximab 
(250 mg/m2 weekly). Patients subsequently received main-
tenance cetuximab for six months. Serious toxicities during 
treatment included grade 3/4 neutropenia, infection, anemia, 
thrombocytopenia, hypomagnesemia, rash, mucositis and 
diarrhea. Longer follow-up is needed for determination of 
loco-regional control and survival endpoints.
Investigators from ECOG conducted a study (ECOG 
2303) of induction carboplatin/paclitaxel and cetux-
imab followed by radiation with carboplatin/paclitaxel 
and cetuximab.57 Six months of maintenance cetuximab was 
given subsequently. Primary site biopsies were completed 
after the induction phase and again after the chemoradiation 
phase with complete pathological responses noted in 65% 
and 100% of samples, respectively.
Investigators from MDACC have also presented data 
integrating cetuximab in an induction regimen with weekly 
carboplatin and paclitaxel.58 This regimen was followed 
by risk-based definitive therapy. The results are promising 
with induction therapy that includes cetuximab resulting in 
a complete response (CR) rate of 19% and partial response 
(PR) of 77%. The 3-year OS rate of 91% in this population 
of patients with regionally metastatic N2/N3 disease was 
encouraging. Six patients had recurrences, 3 of them with T4 
disease. Twelve out of 26 tumors tested were HPV-positive; 
this particular group did not have any recurrences, and 
had a significantly greater PFS and OS compared to the 
HPV-negative patients.
Finally, cetuximab has also been added to the TPF regi-
men (docetaxel, cisplatin and 5-FU), which was investigated 
in a randomized phase III trial and found to have superior 
survival results when compared to the 2-drug combination of 
cisplatin and 5-FU and induction chemotherapy.59,60 A phase 
1 study from Dana-Farber was completed to determine the 
MTD (maximum tolerated dose) of 5-FU in the TPF regi-
men when combined with cetuximab for locally advanced 
HNSCC.61 Nineteen patients were enrolled. There was one 
dose-limiting toxicity (DLT) of febrile neutropenia, and 
gastrointestinal toxicity with grade 4 enteritis was a serious 
DLT necessitating reduction of the 5-FU dose to 850 mg/m2 
to lessen toxicity.
A phase II trial from Spain enrolled 50 patients who 
received induction chemotherapy with cetuximab (400 mg/m2 
loading and 250 mg/m2 weekly) along with TPF (docetaxel 
75 mg/m2, cisplatin 75 mg/m2 and continuous 5-FU 750 mg/m2 
on days 1 to 5 every 3 weeks for 4 cycles).62 This was fol-
lowed by concurrent radiation with weekly cetuximab. There 
was a high ORR of 78% after 4 cycles of induction therapy. 
Grade 3/4 toxicity was significant with neutropenia (24%), 
neutropenic fever (20%), diarrhea (12%), infection (6%), 
thrombocytopenia (4%), hepatotoxicity (4%) and hypomag-
nesemia (2%). There were also 2 treatment-related deaths 
(febrile neutropenia and hepatic insufficiency).
It remains to be proven whether induction chemotherapy 
followed by chemoradiation is better than chemoradiation 
alone. However, preliminary data suggest that it is feasible to 
combine cetuximab with other agents in our efforts to tailor 
an ideal induction therapy regimen for patients with locally Biologics: Targets & Therapy 2010:4 177
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advanced HNSCC. Larger studies are required to study if 
there is any survival benefit to intensifying induction regi-
mens with the addition of cetuximab in both HPV-positive 
and negative patients.
Treatment of recurrent  
or metastatic disease
Treatment options are still too few for patients with locally 
recurrent or metastatic incurable HNSCC. A limited number 
of patients with recurrent disease are candidates for salvage 
therapies, including potentially curative surgery.63 Some 
patients in this setting appear to benefit from re-irradiation 
although the morbidities of this approach can be substantial 
and careful patient selection is key.64 Chemotherapy therefore 
remains the mainstay of treatment for the majority of patients 
with incurable HNSCC.
Prior to the introduction of cetuximab, the most com-
mon regimens for recurrent/metastatic HNSCC included 
cisplatin plus 5-FU, cisplatin plus a taxane or single-agent 
methotrexate.65–67 Bleomycin is also approved in this setting 
but is not a component of contemporary regimens. Response 
rates are higher for combination regimens vs monothera-
pies and regimens containing cisplatin are the most active. 
Nonetheless, over a period of 30 years median survival with 
chemotherapy for this population had remained around 6 to 
7 months with no clear evidence that any variations in the 
chemotherapy regimens, including the introduction of newer 
agents such as taxanes, had any significant additive effects 
on overall survival. The situation is even worse in patients 
failing first-line chemotherapy, especially those patients who 
are demonstrably platinum-resistant. Second-line treatment 
options for incurable platinum-resistant HNSCC were until 
recently practically non-existent.68
Cetuximab in the first-line 
treatment of patients with  
incurable HNSCC
Burtness and co-investigators in ECOG completed the 
first clinical trial (E5397) in 2005 investigating the role of 
cetuximab in the first-line treatment of incurable advanced 
HNSCC.69 117 patients who had not received prior che-
motherapy for recurrent and/or metastatic disease were 
randomized to either cisplatin (100 mg/m2 every 4 weeks) 
with placebo or to cisplatin with cetuximab (400 mg/m2 
loading dose followed by 250 mg/m2 weekly). There was a 
statistically significant improvement in response rate from 
10% to 26% with the addition of cetuximab (P = 0.03) 
with a trend towards an improvement in overall survival 
from 8 to 9.2 months. The 1-year survival rates for the 
cisplatin plus cetuximab and cisplatin plus placebo arms 
were 39% and 32% respectively with corresponding 2-year 
survival rates of 16% and 9%. However, the difference in 
survival was not statistically significant, likely due to a 
lack of power to detect significant survival differences, 
as well as the study design, which allowed cross-over to 
cetuximab of patients who had progressed on the placebo 
arm. In a phase I/II study performed by Bourhis et al, 53 
patients with advanced HNSCC were assigned to treat-
ment in the first-line setting with cetuximab plus platinum 
plus 5-FU.70 Treatment with this triplet showed an overall 
response rate of 36% with a promising median survival 
of 9.76 months.
In a later and much larger phase III study conducted 
in Europe, known as the EXTREME trial, 442 patients 
with advanced HNSCC were randomized to either a 
platinum-containing doublet or a similar doublet with 
cetuximab.71 Patients had not received any prior treatment 
for recurrent/metastatic disease. The chemotherapy 
regimen used was platinum (cisplatin at 100 mg/m2 
or carboplatin AUC 5 on day 1) in combination with 
5-FU 1000 mg/m2 on days 1 to 4 for a maximum of 6 
cycles. Patients randomized to receive cetuximab with 
chemotherapy could continue to receive maintenance 
cetuximab until progression. It is important to note that 
cross-over to cetuximab for those patients initially random-
ized to chemotherapy alone was not allowed in this study. 
The addition of cetuximab showed a statistically signifi-
cant improvement in survival from 7.4 to 10.1 months (P = 
0.036). In a subset analysis, there was a greater benefit 
for the following subgroups: under 65 years of age, better 
performance status and the receipt of cisplatin as opposed 
to carboplatin. These data established the role of cetuximab 
in first-line therapy for advanced HNSCC when given in 
combination with cisplatin and 5-FU.
Cetuximab has also been shown to be active in combi-
nation with paclitaxel in the first-line setting. In a phase II 
study from the Spanish Head and Neck Cancer Group, 
46 patients received first-line treatment with paclitaxel 
given once weekly at 80 mg/m2 plus cetuximab.72 Among 
the 35 evaluable patients, the combined CR and PR rate was 
71% with a disease control rate of 88%. Median PFS was 
5 months. At a median follow-up of 5.6 months, the median 
overall survival had not been reached. This study suggests 
that cetuximab has additive anti-tumor activity with other 
cytotoxic agents.Biologics: Targets & Therapy 2010:4 178
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Cetuximab in disease progressing 
on prior therapy
The anti-tumor activity of cetuximab in patients with 
advanced head and neck cancer was apparent early on in 
phase 1 investigations.73,74 Cisplatin and cetuximab were 
combined in a single-institution phase 1b study of 12 patients, 
6 of whom had received prior systemic therapy after disease 
recurrence.75 In this dose-ranging study, cetuximab was 
administered at 3 different dose levels. A high percentage of 
EGFR binding in tumor tissue was achieved with an initial 
400 mg/m2 loading dose and subsequent weekly doses of 
250 mg/m2. Over all dose levels, 2 CRs and 4 PRs were noted 
among 9 evaluable patients (response rate, 67%).
A major unmet medical need is the treatment of patients 
with incurable HNSCC who failed to respond to platinum-
based chemotherapy. Several published studies have focused 
on this unfortunate patient population. In a European multi-
center phase II trial performed by Baselga et al, 96 patients 
with platinum-refractory disease were treated by adding 
cetuximab to the platinum dose and schedule that the patients 
had previously failed.76 The response rate was 10%, with a 
disease control rate of 53%, median time to progression of 
2.79 months and OS of 6.01 months. In a similar US-based 
phase II study performed by Herbst et al, 130 patients with 
stable disease (SD) or progressive disease (PD) on previous 
platinum therapy, received treatment with cetuximab and 
cisplatin.77 There were 2 PD cohorts: PD1 (n = 25) that had 
patients whose disease progressed on two cycles of protocol-
specified platinum-based therapy and PD2 (n = 54) that had 
patients whose disease progressed within three months of 
any platinum-based therapy. The response rates were 18% for 
the SD cohort, 20% for the PD1 cohort and 6% for the PD2 
cohort with median survivals of 11.7 months, 6.1 months and 
4.3 months, respectively. Other than increased exposure to 
cisplatin in the PD2 cohort, there is little other information 
about biomarkers (such as EGFR expression) to explain the 
striking difference (albeit not statistically significant) in effi-
cacy between these cohorts. These studies made it clear that 
cetuximab was active in these patients. What was not clear 
was whether the observed anti-tumor activity resulted from 
the combination of cisplatin plus cetuximab or if cetuximab 
itself was responsible.
A landmark phase II study led by Vermorken et al 
enrolled 103 patients actively failing platinum-based thera-
pies and treated them with cetuximab as a monotherapy. 
They reported a response rate of 12.6%, disease control rate 
of 46% and median overall survival of 5.84 months.78 Based 
on contemporary data, the expected response rate to second-
line chemotherapy in this population is 2.5%.68 Patients pro-
gressing on cetuximab monotherapy in this trial were given 
the option to receive cetuximab and cisplatin; there were no 
responses among 53 patients who received such combined 
treatment after progressing on cetuximab.
The comparable response rates and median overall sur-
vival (5–6 months) in these three studies support the conclu-
sion that cetuximab monotherapy is the preferred approach 
for platinum-refractory patients with incurable HNSCC. Fur-
thermore, the data in aggregate suggest that chemotherapy in 
this setting probably adds little to the observed response and 
clinical benefit conferred by cetuximab monotherapy. Ver-
morken and colleagues conducted a pooled analysis of these 
three phase II trials.79 The analysis compared the outcome of 
these patients to those in a retrospective study who received a 
range of common second-line treatment approaches including 
best supportive care, palliative chemotherapy, radiotherapy 
and chemoradiotherapy. The median OS for patients in the 
retrospective study was 3.4 months, roughly half the median 
OS time in the three phase II trials investigating the role 
of cetuximab in patients with advanced HNSCC who had 
progressed on platinum-based therapy.
While the study discussed above combining paclitaxel 
and cetuximab allowed patients in the first-line treatment 
setting for recurrent/metastatic disease, investigators have 
also evaluated taxane plus cetuximab therapy in the second-
line setting in platinum pre-treated patients. In a study by 
Knoedler and colleagues, 84 patients received cetuximab and 
Table 1 Phase II studies of cetuximab in disease progressing on prior therapy
Study Treatment Patients (n) Response (%) Disease control  
rate (%)
Median PFS 
(months)
Median OS 
(months)
Baselga et al76 Cetuximab/platinum 96 10 53 2.79 6.01
Herbst et al77 Cetuximab/platinum 155 11.5 NA PD1 (3.0)  
PD2 (2.0)  
SD (4.9)
PD1 (6.1)  
PD2 (4.3)  
SD (11.7)
Vermorken et al78 Cetuximab monotherapy 103 13 46 2.29 5.84
Abbreviations: PFS, progression-free survival; OS, overall survival; NA, not applicable; PD1, patients who progressed on prior platinum therapy on protocol; PD2, patients 
who had prior platinum therapy off study; SD, stable disease.Biologics: Targets & Therapy 2010:4 179
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docetaxel (35 mg/m2 on days 1, 8, 15 of a 4-week cycle) with 
a PR rate of 12%, PFS of 4 months and OS of 7 months.80 
While these numbers are modest, they do indicate some 
activity in a population of patients that tends to be highly 
refractory to therapy. In this phase 2 trial, however, the 
response rate and median survival results are similar to data 
observed in the cetuximab monotherapy studies.
It is reasonable to ask if the addition of other molecu-
larly targeted therapies to cetuximab could achieve further 
improvements in outcome in platinum-refractory patients. 
In addition, nearly all responding patients will eventually 
become resistant to cetuximab, and thus future research is 
required to study ways to bypass resistance mechanisms. 
Preclinical models have suggested that vascular endo-
thelial growth factor (VEGF) production by tumor cells 
may counteract the antitumor effects of EGFR inhibition. 
Thus, there is rationale for combined targeting in order to 
enhance anti-tumor activity. There is an ongoing phase II 
trial by Kies et al for patients with recurrent or metastatic 
HNSCC who have been previously treated with up to 
1 chemotherapy regimen.81 Patients in this study receive 
weekly cetuximab along with bevacizumab every 3 weeks. 
Of 15 evaluable patients at the last interim analysis, 4 had a 
partial response and 8 had stable disease. Grade 3/4 adverse 
events included proteinuria, hypertension, stomatitis, rash 
and fatigue. Results of this trial should provide additional 
insights, especially the planned biomarker analysis related 
to EGFR and angiogenesis.
Tolerability
Cetuximab may cause significant grade 4 infusion reac-
tions in a minority (∼3%) of patients. Interestingly, centers 
in southeastern US note a significantly higher incidence 
of infusion reactions. A recent study showed that 22% of 
patients treated with cetuximab in 3 centers from Tennessee 
and North Carolina had severe hypersensitivity reactions.82 
A history of prior allergy or atopy was identified as a risk 
factor. A study by Chung et al showed that in 17 of 21 patients 
who had experienced such an allergic reaction there were pre-
existing IgE antibodies against galactose-α-1,3-galactose, an 
oligosaccharide present on cetuximab.83 It is unclear why 
people in one area of the country have a strikingly higher 
prevalence of these IgE antibodies against galactose-α-1,3-
galactose, whereas in other areas the incidence of such IgE 
antibodies is very low. Whether one could test for the pres-
ence of such antibodies before administering cetuximab 
and thereby avoid grade 4 infusion reactions is the subject 
of ongoing research.
The most common toxicity of cetuximab occurs in 
the skin with a characteristic acne-like pustular rash often 
accompanied by xerosis, nail changes, paronychia and digital 
fissuring. This is seen in 80% of patients treated with cetux-
imab. EGFR is expressed at the basal layer of the epidermis 
and it is, therefore, not surprising that the skin expresses this 
mechanism-based toxicity.84 The rash is usually managed 
with emollients, topical glucocorticoids, and oral antibiotics 
such as doxycycline and minocycline.
There have also been multiple case-reports of cetuximab-
related ocular toxicities including corneal erosions, keratitis 
and trichomegaly of eyelashes.85–87 These effects are not 
surprising given the role of EGFR family members in the 
cornea healing process.88,89
The presence of rash as a positive predictor of improved 
outcome with EGFR inhibitors including cetuximab was 
suggested initially in studies of cetuximab in HNSCC and 
colorectal cancer. In the phase 2 trial conducted by Herbst 
et al, for example, patients without rash had a response 
rate of 0% and 1-year survival of 18% compared to a 25% 
response rate and 1-year survival of 55% in those with 
grade 2 or 3 rash.77
Despite the skin toxicities caused by cetuximab, the 
risk of poor wound healing appears to be low. In a subset 
analysis of 39 patients treated with radiation or radiation 
plus cetuximab who then proceeded to have neck dissec-
tions (6–8 weeks after treatment), there was no significant 
differences in time to healing or complication rates between 
the two groups.90 A retrospective case series of 35 patients 
who underwent salvage neck dissections after treatment with 
radiation alone or with cetuximab also showed no significant 
increase in risk for post-surgical wound complications –2 of 
15 patients treated with radiation and cetuximab had wound 
healing complications while no complications occurred in 
the 20 patients who received radiation alone (P = 0.20).91 
It will be important to continue collecting data on patients 
undergoing major surgery who have received EGFR inhibi-
tor therapy.
Hypomagnesemia is another class effect associated with 
anti-EGFR antibodies, including cetuximab. This appears 
to be due to inhibition of magnesium reabsorption in the 
ascending loop of Henle, which is a direct consequence 
of EGFR blockade in the kidney. Routine monitoring and 
repletion of potassium and magnesium is therefore necessary 
in patients receiving cetuximab. The onset of hypomagnese-
mia starts shortly after initiation of cetuximab and resolves 
within weeks of discontinuation. However, in patients with 
metastatic disease who require long-term treatment with Biologics: Targets & Therapy 2010:4 180
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cetuximab, ongoing magnesium supplementation may be 
necessary, including parenteral replacement.
Overall, cetuximab treatment has an acceptable toler-
ability profile, with the majority of adverse events being 
mild or moderate in severity and clinically manageable. 
Of note, in the clinical trials to date, it has been feasible to 
combine cetuximab with diverse cytotoxic chemotherapy 
regimens without significantly increasing the adverse effects 
commonly seen with such regimens when given without 
cetuximab. In the EXTREME trial, for example, there was 
no significant difference in the overall incidence of grade 3 
or 4 adverse events between the groups except for skin reac-
tions (P  0.001), hypomagnesemia (P = 0.05), anorexia 
(P = 0.05) and sepsis (P = 0.02).71
Ongoing and future studies  
with cetuximab in recurrent/
metastatic disease
While cetuximab does result in improved survival in com-
bination with chemotherapy and radiation, single agent 
response rates in the platinum-refractory setting are modest. 
Alternate (bypass) signaling pathways are undoubtedly 
responsible for resistance to cetuximab. Targets of interest 
include angiogenesis, the insulin-like growth factor recep-
tor (IGF-1R), the phospho-inositol 3 kinase/Akt/mTOR 
axis, and Src. There are a number of available agents that 
antagonize these pathways and therefore might have utility 
in combination with cetuximab to overcome such resistance. 
In particular, inhibition of IGF-1R is actively being studied 
in head and neck cancer. Preclinical data from head and neck 
cell lines have indicated that IGR-1R is elevated compared 
to normal tissue. In addition, treatment of head and neck 
tumor xenografts with cetuximab and the IGF-1R mono-
clonal antibody IMC-A12 resulted in tumor regression.92 
Clinical trials are underway to evaluate this combination 
in the clinic.
Activated Akt has been shown to be associated with a 
worse prognosis in HNSCC as well, and trials are under-
way to study the safety and effectiveness of combining 
cetuximab and drugs inhibiting mTOR, a target down-
stream from Akt.93 Preclinical data have shown that the 
mTOR inhibitor rapamycin has anti-tumor activity in 
HNSCC in vivo.94 Thus, trials are ongoing to assess the 
activity of newer generation of mTOR inhibitors (temsiro-
limus, everolimus) with cisplatin and cetuximab in patients 
with metastatic disease.
The Src family of kinases has been implicated in the 
pathogenesis of head and neck cancer.95,96 In addition, 
Grandis and colleagues have shown that combined inhibi-
tion of the Src and EGFR kinases inhibits HNSCC cell 
growth and invasion.97 Currently, there is an ongoing phase I 
study to test the safety of cetuximab and the Src inhibitor 
dasatinib in patients with advanced malignancies, which 
will provide more clinical data with regards to the safety of 
this combination.
Table 3 lists selected studies that are ongoing to assess the 
safety and effectiveness of cetuximab in combination with 
novel targeted agents. As these studies evolve and move into 
efficacy studies in selected diseases including HNSCC, we 
will learn whether combining targeted agents with cetuximab 
will have more of an impact on the treatment of recurrent 
disease and the mitigation of resistance to cetuximab-based 
therapies.
Biomarkers of response
While cetuximab is a promising treatment for HNSCC, 
response rates to cetuximab monotherapy are low, and 
clearly not all patients benefit from this drug. There is a 
great deal of interest in the field to determine biomarkers 
that could predict response to therapy. In E5397, analysis 
of EGFR expression levels was performed and the results 
correlated with patient outcomes.69 Tumors were classi-
fied as very high EGFR immunoreactive if 3+ staining 
was present on 80% of cells and low-moderate if there 
was a lesser degree of staining. The treatment groups were 
well-balanced with regard to the EGFR immunoreactivity 
Table 2 Studies of cetuximab in the first-line setting for recurrent/metastatic disease
Study Treatment Patients (n) Response (%) Median PFS (months) Median OS (months)
Burtness et al69 CDDP 57 10 2.7 8
CDDP/cetuximab 60 26 (P = 0.03) 4.2 (P = 0.09) 9.2 (NS)
Hitt et al72 Cetuximab/paclitaxel 46 71 5 NA
Vermorken et al71 CDDP/FU 220 20 3.3 7.4
  CDDP/FU/cetuximab 222 36 (P  0.001) 5.6 (P  0.001) 10.1 (P = 0.036)
Abbreviations: PFS, progression-free survival; OS, overall survival; CDDP, cisplatin; FU, fluorouracil; NA, not applicable.Biologics: Targets & Therapy 2010:4 181
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scores, with about a third of the patients in each group 
having very high immunoreactivity. The addition of cetux-
imab significantly increased response rate in the moderate 
staining group, with no apparent benefit from the addition 
of cetuximab for the high immunoreactive group. Thus, it 
was hypothesized that EGFR expression could be a marker 
for cetuximab activity, with high EGFR expressing tumors 
being more resistant to cetuximab, perhaps due to the 
inability to fully saturate a greater number of receptors 
with the drug. This observation has not been confirmed, 
however, in subsequent studies, including the EXTREME 
trial, in which the high EGFR expressors did derive a sur-
vival benefit from cetuximab-containing therapy. In addi-
tion, tissue from the phase II trial by Herbst and colleagues 
discussed above was analyzed using the EGFR staining 
intensity and density scoring system, and also showed 
that EGFR expression levels did not predict for response 
to cetuximab.98 Thus, this methodology does not appear 
to be a useful approach to guide therapy. It is not known 
if newer automated, quantitative immunohistochemical 
techniques, which allow for more precise quantification of 
EGFR levels as well as subcellular localization will have 
more power to predict for cetuximab response.
EGFR gene copy number detected by FISH (fluorescence 
in situ hybridization) has been analyzed as well. In one retro-
spective study, 63% of HNSCC tumors had high EGFR gene 
copy numbers, which were associated with a trend towards 
an inferior recurrence-free survival.99 However, when tumors 
from the EXTREME trial were analyzed for EGFR gene 
copy number by FISH, being FISH+ with this methodology 
was not a predictive marker for cetuximab efficacy.100 Thus, 
increased EGFR copy number was not associated with an 
improvement in overall survival in either treatment arm or a 
response to cetuximab.
Finally, there are more recent data regarding the potential 
utility of matrix-assisted laser desorption ionization (MALDI) 
mass spectrometry (MS) to predict which patients may ben-
efit from EGFR inhibitors. Utilizing MALDI-MS to analyze 
serum, Chung and colleagues have identified a favorable pro-
teomic profile that may predict for response to cetuximab.101 In 
a retrospective analysis of 314 patient samples, the favorable 
profile predicted for a survival benefit in cohorts of patients 
that were treated with EGFR inhibitors. This proteomic profile 
did not predict for an increase in survival in a control group of 
patients that were not treated with EGFR inhibitors. This novel 
technique will need to be studied more in future studies.
Table 3 Ongoing studies combining cetuximab with novel agents for recurrent/metastatic disease (available on clinicaltrials.gov)
Title Treatment Phase Sample size Study drug target
A phase II trial of cetuximab and  
  bevacizumab in patients with recurrent  
or metastatic head and neck cancer 
NCT00409565
cetuximab 400 mg/m2 loading  
  followed by 250 mg/m2 weekly,  
  bevacizumab 15 mg/kg q21 days
II 48 VEGF
Cetuximab with or without sorafenib 
tosylate in treating patients with refractory,  
recurrent and/or metastatic head and  
neck cancer NCT00939627
cetuximab weekly, placebo versus 
cetuximab weekly, sorafenib twice  
daily days 1–21
II 88 Raf;   VEGFR 1, 2, 3;  
Flt-3; PDGFR β; 
c-kit, RET
Cilengitide in recurrent and/or  
metastatic squamous cell carcinoma  
of the head and neck NCT00705016
Cilengitide, cetuximab, cisplatin,  
5FU vs cetuximab, cisplatin, 5FU
I/II 195 Integrins
Study of IMC-A12, alone or in combination 
with cetuximab, in patients with recurrent  
or metastatic squamous cell carcinoma  
of the head and neck NCT00617734
IMC-A12 ± cetuximab II 90 IGF-1R
BIBW 2992 in head and neck cancer 
NCT00514943
cetuximab vs BIBW2992 II 100 EGFR, Her-2/neu
Phase I study of cetuximab and RAD001 cetuximab and RAD001 I mTOR
Cisplatin, cetuximab and temsirolimus  
in HNSCC NCT01015664
cisplatin, cetuximab, temsirolimus I/II 56 mTOR
RAD001 in combination with cetuximab  
and cisplatin in recurrent/metastatic  
HNSCC NCT01009346
cisplatin, cetuximab, RAD001 I/II 98 mTOR
Safety study of cetuximab plus  
dasatinib (BMS-354825) NCT00388427
cetuximab and dasatinib I 30 SrcBiologics: Targets & Therapy 2010:4 182
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Conclusions and future  
directions for the treatment  
of advanced disease
Cetuximab is now firmly established as an active treatment 
either alone or in combination with radiation or chemo-
therapy for the treatment of advanced recurrent/metastatic 
HNSCC. It is clear that in the first-line treatment setting for 
recurrent/metastatic disease, the addition of cetuximab to 
a platinum doublet significantly improves overall median 
survival of patients with incurable HNSCC. For those 
patients who have not received cetuximab previously for 
recurrent/metastatic disease and who are platinum refrac-
tory, cetuximab monotherapy has emerged as the standard 
of care with response rates that are superior to those seen 
with any second-line chemotherapy drug in this setting.78 The 
limited data available with cetuximab and taxanes suggest 
that this may be an active combination as well, especially 
for patients who cannot receive platinum drugs. There are 
currently no randomized clinical trials data comparing a 
taxane/cetuximab regimen to cetuximab alone in any set-
ting, and therefore we do not know the true magnitude of 
the contribution of cetuximab to the activity of the regi-
men. Given the paucity of treatment options for this patient 
population, participation in clinical trials assessing novel 
combinations that incorporate cetuximab remains a very 
reasonable approach.
Determining biomarkers that could predict for a response 
and survival benefit with cetuximab will be a key focus of 
future studies. We also do not understand the determinants 
of de novo or acquired resistance to cetuximab. We suspect 
that tumors with an EGFR vIII variant and therefore lacking 
the cetuximab-binding domain will be resistant, but this has 
not been formally shown. In addition, as patients are exposed 
to EGFR inhibitors earlier in the treatment course and in 
some cases as part of their initial treatment with radiation 
for curative intent, the utility of re-treatment with cetuximab 
for recurrent disease is unknown.
A major focus of ongoing and future research is to study 
the safety and efficacy of cetuximab in combination with 
other EGFR inhibitors as well as other targeted therapies. 
Currently, trials are underway evaluating simultaneous 
targeting of multiple signaling pathways such as EGFR, 
insulin-like growth factor receptor, Akt and Src. For patients 
who have a hypersensitivity reaction to cetuximab, panitu-
mumab may be a reasonable alternative although data from 
studies testing the activity of panitumumab in HNSCC are 
still quite limited.
The conventional loading dose, followed by a weekly 
maintenance schedule of cetuximab has been used in all of 
the clinical trials leading to its approval. This schedule can be 
inconvenient for patients though, as it requires weekly infu-
sion room visits. There is an ongoing trial to study cetuximab 
dosing on an every-other-week schedule.102 If this proves to 
be feasible and efficacious, it may support future research 
to validate the every-other-week schedule as therapeutically 
equivalent to the conventional weekly schedule.
Finally, HNSCC that is related to the human papillomavirus 
(HPV) is emerging as a different disease compared to the tradi-
tional smoking- and alcohol-related HNSCC. HPV-associated 
HNSCC has been shown to have a generally favorable prognosis, 
and these tumors tend to be chemotherapy and radiotherapy 
sensitive.6 In a small study utilizing induction therapy for 
locally advanced HNSCC, tumors that were HPV , p16+ had an 
increased response to platinum and 5-FU.103 Biomarker analysis 
of the patient samples also indicated that HPV status and EGFR 
expression by immunohistochemistry were inversely related, 
with HPV+, low EGFR expressor having the best response to 
treatment and prognosis.104 Patients in this study did not receive 
cetuximab as part of their induction regimen, and therefore it is 
not known how the favorable prognosis group would respond to 
EGFR inhibition. Given the data, although from a small series, 
that HPV+ tumors have lower EGFR expression, one important 
question is whether cetuximab will improve the outcome of 
HPV+ disease in combination with chemotherapy. An even 
more provocative idea is whether cetuximab could be used in 
place of cytotoxic therapy. Analysis of specimens from exist-
ing studies will likely provide more insight into the biology of 
HPV+ HNSCC. In the future, trials will probably study these 
two subtypes of HNSCC separately, and in that context it will be 
useful to determine how effective cetuximab is for the treatment 
of HPV+, p16+ HNSCC.105
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